<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35578732</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">1054-2523</ISSN>
          <JournalIssue CitedMedium="Print">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents</Title>
          <ISOAbbreviation>Med Chem Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>7</EndPage>
          <MedlinePgn>1-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00044-022-02903-0</ELocationID>
        <Abstract>
          <AbstractText>The COVID-19 pandemic spurred a broad interest in antiviral drug discovery. The SARS-CoV-2 main protease (M<sup>pro</sup>) and papain-like protease (PL<sup>pro</sup>) are attractive antiviral drug targets given their vital roles in viral replication and modulation of host immune response. Structurally disparate compounds were reported as M<sup>pro</sup> and PL<sup>pro</sup> inhibitors from either drug repurposing or rational design. Two polyphenols dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) were recently reported as SARS-CoV-2 M<sup>pro</sup> inhibitors. With our continuous interest in studying the mechanism of inhibition and resistance of M<sup>pro</sup> inhibitors, we report herein our independent validation/invalidation of these two natural products. Our FRET-based enzymatic assay showed that neither dieckol nor PGG inhibited SARS-CoV-2 M<sup>pro</sup> (IC<sub>50</sub> &gt; 20 µM), which is in contrary to previous reports. Serendipitously, PGG was found to inhibit the SARS-CoV-2 PL<sup>pro</sup> with an IC<sub>50</sub> of 3.90 µM. The binding of PGG to PL<sup>pro</sup> was further confirmed in the thermal shift assay. However, PGG was cytotoxic in 293T-ACE2 cells (CC<sub>50</sub> = 7.7 µM), so its intracellular PL<sup>pro</sup> inhibitory activity could not be quantified by the cell-based Flip-GFP PL<sup>pro</sup> assay. In addition, we also invalidated ebselen, disulfiram, carmofur, PX12, and tideglusib as SARS-CoV-2 PL<sup>pro</sup> inhibitors using the Flip-GFP assay. Overall, our results call for stringent hit validation, and the serendipitous discovery of PGG as a putative PL<sup>pro</sup> inhibitor might worth further pursuing. Graphical abstract.</AbstractText>
          <CopyrightInformation>© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Haozhou</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ 08854 USA.</Affiliation>
              <Identifier Source="GRID">grid.430387.b</Identifier>
              <Identifier Source="ISNI">0000 0004 1936 8796</Identifier>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Chunlong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721 USA.</Affiliation>
              <Identifier Source="GRID">grid.134563.6</Identifier>
              <Identifier Source="ISNI">0000 0001 2168 186X</Identifier>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-4845-4621</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ 08854 USA.</Affiliation>
              <Identifier Source="GRID">grid.430387.b</Identifier>
              <Identifier Source="ISNI">0000 0004 1936 8796</Identifier>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AI147325</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AI157046</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AI158775</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Med Chem Res</MedlineTA>
        <NlmUniqueID>9211347</NlmUniqueID>
        <ISSNLinking>1054-2523</ISSNLinking>
      </MedlineJournalInfo>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="UpdateOf">
          <RefSource>Res Sq. 2022 Mar 30;:</RefSource>
          <PMID Version="1">35378761</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antiviral</Keyword>
        <Keyword MajorTopicYN="N">Coronavirus</Keyword>
        <Keyword MajorTopicYN="N">Main protease</Keyword>
        <Keyword MajorTopicYN="N">Papain-like protease</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interestThe authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>1</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35578732</ArticleId>
        <ArticleId IdType="pmc">PMC9095416</ArticleId>
        <ArticleId IdType="doi">10.1007/s00044-022-02903-0</ArticleId>
        <ArticleId IdType="pii">2903</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–54. doi: 10.1038/s41579-020-00459-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId>
            <ArticleId IdType="pmc">PMC7537588</ArticleId>
            <ArticleId IdType="pubmed">33024307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155–70. doi: 10.1038/s41579-020-00468-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId>
            <ArticleId IdType="pmc">PMC7592455</ArticleId>
            <ArticleId IdType="pubmed">33116300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al.  A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–68. doi: 10.1038/s41586-020-2286-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId>
            <ArticleId IdType="pmc">PMC7431030</ArticleId>
            <ArticleId IdType="pubmed">32353859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381–5. doi: 10.1038/nature17180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature17180</ArticleId>
            <ArticleId IdType="pmc">PMC5551389</ArticleId>
            <ArticleId IdType="pubmed">26934220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:eaal3653. doi: 10.1126/scitranslmed.aal3653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aal3653</ArticleId>
            <ArticleId IdType="pmc">PMC5567817</ArticleId>
            <ArticleId IdType="pubmed">28659436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al.  Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6:672–83. doi: 10.1021/acscentsci.0c00489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acscentsci.0c00489</ArticleId>
            <ArticleId IdType="pmc">PMC7202249</ArticleId>
            <ArticleId IdType="pubmed">32483554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021;6:11–8. doi: 10.1038/s41564-020-00835-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41564-020-00835-2</ArticleId>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M, Yoon J-J, Cox RM, Hart M, Sticher ZM, Makhsous N, et al.  Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019;11:eaax5866. doi: 10.1126/scitranslmed.aax5866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aax5866</ArticleId>
            <ArticleId IdType="pmc">PMC6848974</ArticleId>
            <ArticleId IdType="pubmed">31645453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghosh AK, Brindisi M, Shahabi D, Chapman ME, Mesecar AD. Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics. ChemMedChem. 2020;15:907–32. doi: 10.1002/cmdc.202000223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cmdc.202000223</ArticleId>
            <ArticleId IdType="pmc">PMC7264561</ArticleId>
            <ArticleId IdType="pubmed">32324951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, et al.  Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;30:678–92. doi: 10.1038/s41422-020-0356-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-020-0356-z</ArticleId>
            <ArticleId IdType="pmc">PMC7294525</ArticleId>
            <ArticleId IdType="pubmed">32541865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, et al.  Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun. 2020;11:4417. doi: 10.1038/s41467-020-18233-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-18233-x</ArticleId>
            <ArticleId IdType="pmc">PMC7474075</ArticleId>
            <ArticleId IdType="pubmed">32887884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vuong W, Khan MB, Fischer C, Arutyunova E, Lamer T, Shields J, et al.  Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun. 2020;11:4282. doi: 10.1038/s41467-020-18096-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-18096-2</ArticleId>
            <ArticleId IdType="pmc">PMC7453019</ArticleId>
            <ArticleId IdType="pubmed">32855413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drayman N, DeMarco JK, Jones KA, Azizi S-A, Froggatt HM, Tan K, et al.  Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021;373:931–6. doi: 10.1126/science.abg5827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abg5827</ArticleId>
            <ArticleId IdType="pmc">PMC8809056</ArticleId>
            <ArticleId IdType="pubmed">34285133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osipiuk J, Azizi SA, Dvorkin S, Endres M, Jedrzejczak R, Jones KA, et al.  Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat Commun. 2021;12:743. doi: 10.1038/s41467-021-21060-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-21060-3</ArticleId>
            <ArticleId IdType="pmc">PMC7854729</ArticleId>
            <ArticleId IdType="pubmed">33531496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Sacco MD, Xia Z, Lambrinidis G, Townsend JA, Hu Y, et al.  Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay. ACS Cent Sci. 2021;7:1245–60. doi: 10.1021/acscentsci.1c00519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acscentsci.1c00519</ArticleId>
            <ArticleId IdType="pmc">PMC8265724</ArticleId>
            <ArticleId IdType="pubmed">34341772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Du X, Duan Y, Pan X, Sun Y, You T, et al.  High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein Cell. 2021;12:877–88. doi: 10.1007/s13238-021-00836-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13238-021-00836-9</ArticleId>
            <ArticleId IdType="pmc">PMC8052528</ArticleId>
            <ArticleId IdType="pubmed">33864621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swaim CD, Dwivedi V, Perng YC, Zhao X, Canadeo LA, Harastani HH, et al.  6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro. iScience. 2021;24:103213. doi: 10.1016/j.isci.2021.103213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.isci.2021.103213</ArticleId>
            <ArticleId IdType="pmc">PMC8487320</ArticleId>
            <ArticleId IdType="pubmed">34632326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho CC, Li SG, Lalonde TJ, Yang KS, Yu G, Qiao Y, et al.  Drug repurposing for the SARS-CoV-2 papain-like protease. ChemMedChem. 2022;17:e202100455. doi: 10.1002/cmdc.202100455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cmdc.202100455</ArticleId>
            <ArticleId IdType="pmc">PMC8653067</ArticleId>
            <ArticleId IdType="pubmed">34423563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christy MP, Uekusa Y, Gerwick L, Gerwick WH. Natural products with potential to treat RNA virus pathogens including SARS-CoV-2. J Nat Prod. 2021;84:161–82. doi: 10.1021/acs.jnatprod.0c00968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jnatprod.0c00968</ArticleId>
            <ArticleId IdType="pmc">PMC7771248</ArticleId>
            <ArticleId IdType="pubmed">33352046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakravarti R, Singh R, Ghosh A, Dey D, Sharma P, Velayutham R, et al.  A review on potential of natural products in the management of COVID-19. RSC Adv. 2021;11:16711–35. doi: 10.1039/D1RA00644D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D1RA00644D</ArticleId>
            <ArticleId IdType="pmc">PMC9031656</ArticleId>
            <ArticleId IdType="pubmed">35479175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan G, Li D, Lin Y, Fu Z, Qi H, Liu X, et al.  Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors. Cell Biosci. 2021;11:199. doi: 10.1186/s13578-021-00720-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13578-021-00720-3</ArticleId>
            <ArticleId IdType="pmc">PMC8645223</ArticleId>
            <ArticleId IdType="pubmed">34865653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiou W-C, Chen J-C, Chen Y-T, Yang J-M, Hwang L-H, Lyu Y-S, et al.  The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease. Biochem Biophys Res Commun. 2022;591:130–6. doi: 10.1016/j.bbrc.2020.12.106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2020.12.106</ArticleId>
            <ArticleId IdType="pmc">PMC7787066</ArticleId>
            <ArticleId IdType="pubmed">33454058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Wang J. Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors. ACS Pharm Transl Sci. 2022;5:102–9. doi: 10.1021/acsptsci.1c00240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsptsci.1c00240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Tan H, Choza J, Wang Y, Wang J. Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Acta Pharm Sin B. 2022;12:1636–51. doi: 10.1016/j.apsb.2021.10.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.apsb.2021.10.026</ArticleId>
            <ArticleId IdType="pmc">PMC8558150</ArticleId>
            <ArticleId IdType="pubmed">34745850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Hu Y, Townsend JA, Lagarias PI, Marty MT, Kolocouris A, et al.  Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors. ACS Pharm Transl Sci. 2020;3:1265–77. doi: 10.1021/acsptsci.0c00130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsptsci.0c00130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Wang J. Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci USA. 2021;118:e2024420118. doi: 10.1073/pnas.2024420118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2024420118</ArticleId>
            <ArticleId IdType="pmc">PMC7923551</ArticleId>
            <ArticleId IdType="pubmed">33568498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al.  Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–93. doi: 10.1038/s41586-020-2223-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId>
            <ArticleId IdType="pubmed">32272481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin MH, Moses DC, Hsieh CH, Cheng SC, Chen YH, Sun CY, et al.  Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antivir Res. 2018;150:155–63. doi: 10.1016/j.antiviral.2017.12.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.antiviral.2017.12.015</ArticleId>
            <ArticleId IdType="pmc">PMC7113793</ArticleId>
            <ArticleId IdType="pubmed">29289665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weglarz-Tomczak E, Tomczak JM, Talma M, Burda-Grabowska M, Giurg M, Brul S. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2. Sci Rep. 2021;11:3640. doi: 10.1038/s41598-021-83229-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-83229-6</ArticleId>
            <ArticleId IdType="pmc">PMC7878891</ArticleId>
            <ArticleId IdType="pubmed">33574416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J-Y, Kim JH, Kwon JM, Kwon H-J, Jeong HJ, Kim YM, et al.  Dieckol, a SARS-CoV 3CLpro inhibitor, isolated from the edible brown algae Ecklonia cava. Bioorg Med Chem. 2013;21:3730–7. doi: 10.1016/j.bmc.2013.04.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmc.2013.04.026</ArticleId>
            <ArticleId IdType="pmc">PMC7126891</ArticleId>
            <ArticleId IdType="pubmed">23647823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen RH, Yang LJ, Hamdoun S, Chung SK, Lam CW-K, Zhang KX et al. 1,2,3,4,6-pentagalloyl glucose, a RBD-ACE2 binding inhibitor to prevent SARS-CoV-2 infection. Front Pharmacol. 2021;12. 10.3389/fphar.2021.634176.</Citation>
        </Reference>
        <Reference>
          <Citation>Froggatt HM, Heaton BE, Heaton NS. Development of a fluorescence-based, high-throughput SARS-CoV-2 3CL(pro) reporter assay. J Virol. 2020;94:e01265–20. doi: 10.1128/JVI.01265-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01265-20</ArticleId>
            <ArticleId IdType="pmc">PMC7592234</ArticleId>
            <ArticleId IdType="pubmed">32843534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Lidsky PV, Xiao Y, Wu CT, Garcia-Knight M, Yang J, et al.  Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. PLoS Pathog. 2021;17:e1009898. doi: 10.1371/journal.ppat.1009898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1009898</ArticleId>
            <ArticleId IdType="pmc">PMC8445489</ArticleId>
            <ArticleId IdType="pubmed">34478458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sargsyan K, Lin CC, Chen T, Grauffel C, Chen YP, Yang WZ, et al.  Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors. Chem Sci. 2020;11:9904–9. doi: 10.1039/d0sc02646h.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/d0sc02646h</ArticleId>
            <ArticleId IdType="pmc">PMC8162115</ArticleId>
            <ArticleId IdType="pubmed">34094251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amporndanai K, Meng X, Shang W, Jin Z, Rogers M, Zhao Y, et al.  Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nat Commun. 2021;12:3061. doi: 10.1038/s41467-021-23313-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-23313-7</ArticleId>
            <ArticleId IdType="pmc">PMC8144557</ArticleId>
            <ArticleId IdType="pubmed">34031399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sacco MD, Ma C, Lagarias P, Gao A, Townsend JA, Meng X, et al.  Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L. Sci Adv. 2020;6:eabe0751. doi: 10.1126/sciadv.abe0751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.abe0751</ArticleId>
            <ArticleId IdType="pmc">PMC7725459</ArticleId>
            <ArticleId IdType="pubmed">33158912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Xia Z, Sacco MD, Hu Y, Townsend JA, Meng X, et al.  Discovery of di- and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity. J Am Chem Soc. 2021;143:20697–709. doi: 10.1021/jacs.1c08060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jacs.1c08060</ArticleId>
            <ArticleId IdType="pmc">PMC8672434</ArticleId>
            <ArticleId IdType="pubmed">34860011</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
